Madrigal Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $212,802 | $137,250 | $103,320 | $62,175 |
Gross Profit | 203,360 | 132,358 | 99,512 | 59,725 |
EBITDA | -38,640 | -69,562 | -55,555 | -102,987 |
EBIT | -39,017 | -69,941 | -55,918 | -103,285 |
Net Income | -42,281 | -73,238 | -59,416 | -106,964 |
Net Change In Cash | 212,802 | 137,250 | 103,320 | 62,175 |
Free Cash Flow | -47,052 | -88,891 | -104,681 | -67,763 |
Cash | 191,193 | 183,646 | 100,019 | 232,684 |
Basic Shares | 22,207 | 22,091 | 21,273 | 21,746 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $180,133 | $0 | $0 | $37 |
Gross Profit | 172,804 | -527 | -467 | 273 |
EBITDA | -450,125 | -360,391 | -290,919 | -242,077 |
EBIT | -451,221 | -360,918 | -291,386 | -242,482 |
Net Income | -465,892 | -373,630 | -295,350 | -241,078 |
Net Change In Cash | 180,133 | 0 | 0 | 37 |
Cost of Revenue | 295,280 | -17,735 | ||
Free Cash Flow | -457,034 | -325,709 | -225,074 | -184,126 |
Cash | 100,019 | 99,915 | 331,549 | 36,269 |
Basic Shares | 21,273 | 18,688 | 17,137 | 16,535 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$1.90 |
2025-03-31 | -$3.32 |
2024-12-31 | -$2.71 |
2024-09-30 | -$4.92 |
